| Q34354736 | Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome |
| Q35953274 | African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV) |
| Q36955395 | Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis |
| Q34790028 | Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis |
| Q35953541 | Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome |
| Q44620496 | Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chains |
| Q34504768 | Antibodies and vascular involvement in inflammatory joint disease: clinical relevance |
| Q57825441 | Antiphospholipid Antibodies in Patients with Lupus Nephritis |
| Q37318783 | Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome |
| Q34005307 | Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort |
| Q41682862 | Antiphospholipid antibodies or not? The role of beta 2 glycoprotein 1 in autoantibody-mediated pregnancy loss |
| Q28193967 | Antiphospholipid antibodies: biological basis and prospects for treatment |
| Q36832522 | Antiphospholipid antibody effects on monocytes |
| Q34271982 | Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis |
| Q77746573 | Apoptosis and antiphospholipid antibodies |
| Q73251576 | Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease |
| Q35148621 | Atherosclerosis and antiphospholipid syndrome |
| Q34504806 | Atherosclerosis and connective tissue diseases |
| Q37033339 | Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q84430476 | Atherosclerosis risk factors in systemic lupus erythematosus |
| Q37824302 | Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases |
| Q35172086 | Autoantibody-mediated atherosclerosis |
| Q33976585 | Autoimmunity in atherosclerosis. The role of autoantigens |
| Q37606350 | Autoimmunity, infectious immunity, and atherosclerosis |
| Q40975353 | Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage |
| Q54483428 | Beta2GP-I in the anti phospholipid (Hughes') syndrome--from a cofactor to an autoantigen--from induction to prevention of antiphospholipid syndrome. |
| Q44300088 | Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen |
| Q38209471 | Clinical relevance of β₂-glycoprotein-I plasma levels in antiphospholipid syndrome (APS). |
| Q40585799 | Cloning and characterization of the human beta2-glycoprotein I (beta2-GPI) gene promoter: roles of the atypical TATA box and hepatic nuclear factor-1alpha in regulating beta2-GPI promoter activity |
| Q73128263 | Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes |
| Q64240565 | Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension |
| Q43801367 | Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome |
| Q22254095 | High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II |
| Q37316712 | Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis |
| Q89544090 | Impaired ankle-brachial index in antiphospholipid syndrome: Beyond the traditional risk factors |
| Q37351603 | Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients |
| Q35549285 | Inflammation-mediated rheumatic diseases and atherosclerosis |
| Q42866736 | Intestinal Angina Due to Atherosclerosis in a 45-year-old Systemic Lupus Erythematosus Patient |
| Q36359710 | Intravenous immunoglobulin and atherosclerosis |
| Q35123740 | Is atherosclerosis an autoimmune disease? |
| Q36932166 | Is preclinical autoimmunity benign?: The case of cardiovascular disease |
| Q36577423 | Mechanisms of disease: atherosclerosis in autoimmune diseases |
| Q37726701 | Natural killer T cells and atherosclerosis: form and function meet pathogenesis |
| Q44138798 | Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages |
| Q26747100 | Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role |
| Q58802965 | Pro‑atherogenic activation of A7r5 cells induced by the oxLDL/β2GPI/anti‑β2GPI complex |
| Q28392431 | Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management |
| Q64887718 | Receptors for oxidized low density lipoprotein. |
| Q36596956 | Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H) |
| Q48565507 | Serum oxLDL-β2GPI complex reflects metabolic syndrome and inflammation in adipose tissue in obese |
| Q52036049 | Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. |
| Q36960925 | Systemic antiphospholipid syndrome and atherosclerosis |
| Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
| Q38029695 | Targeted interception of signaling reactive oxygen species in the vascular endothelium |
| Q92309474 | The Role of Cardiolipin and Mitochondrial Damage in Kidney Transplant |
| Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
| Q34400681 | The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians |
| Q50417164 | The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity. |
| Q36821493 | The role of preventive cardiology in systemic lupus erythematosus |
| Q28188901 | Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease |
| Q35692035 | Vaccination and atherosclerosis |
| Q81575733 | [Cardiovascular monitoring of patients with systemic lupus erythematosus] |
| Q80509635 | [Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndromeand systemic lupus erythematosus] |
| Q74348150 | beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis |